WHO approves clinical trials of Kazakh COVID-19 vaccine
The World Health Organization has officially included Kazakh inactivated vaccine against COVID-19 in the list of candidate vaccines approved for clinical trials, the WHO website stated. The table indicates that Kazakh COVID-19 vaccine based on inactivated virus is in Phase 1/2 of clinical trial.
The list of COVID-19 candidate vaccines that undergo clinical evaluation includes 33 vaccines developed by companies or research institutes from 19 countries, including the United Kingdom, China, Russia, the United States, Germany, Japan, India, South Korea, Belgium, Sweden, Singapore, Italy, Australia, Taiwan, Cuba, France, Austria and Canada.
The Research Institute for Biological Safety Problems of the Science Committee of Kazakh Ministry of Education and Science started the development of the first vaccine against the novel coronavirus at the end of March.
Later, the relevant ministry reported how the Kazakh COVID-19 vaccine is being tested. Preclinical trials of the vaccine were completed in August, and clinical trials in humans will begin already in September.